



BRAF CODON 600 VARIANT ANALYSIS

Patient Details		Source Information		Sample Information	
Lab Number:	MP19- XXXX	Requester Ref:		Date Received:	01/01/2019
Surname:	Atient	Surgical No.:	18S 0001 A1	Primary Tumour Site:	Skin
Forename:	Peter	Sample Type:	FFPE Block	Tumour Subtype:	Melanoma
D.O.B. (D/M/Y)	01/05/1964	Consultant:	Consultant	Tissue Sample Site:	Skin
Gender:	Male	Hospital:	Random DGH	(Whole):	51-75%
Run:	B999			% Tumour (Selected):	

Results

Detected DNA Change: c.1798_1799delinsAA

Detected Protein Change: p.(Val600Lys)

Mutation Status Summary:

There is evidence of BRAF codon 600 mutation in this sample. In melanoma patients, this has been associated with an increased likelihood of response to BRAF-targeted therapy.

Other Comments:

None

Approved by:

Signature:

Name: Dr F. Irst Date: 07/10/2019

Job Title:

Clinical Scientist ✓
Consultant Histopathologist
BMS (senior)

Checked by:

Signature:

Name: Dr S. Econd Date: 07/10/2019

Job Title:

BMS
Trainee Clinical Scientist / BMS
Molecular Biology, PhD ✓

This assay was performed on a Qiagen RotorGene-Q QPCR system using the Therascreen BRAF RGQ PCR Kit. This assay is CE-IVD certified for use on samples with >5% tumour content, with an analytical sensitivity of approximately 5% variant frequency and can detect the following mutations; p.Val600Glu (c.1799T>A or c.1799_1800delinsAA), p.Val600Asp (c.1799_1800delinsAT), p.Val600Lys (c.1798_1799delinsAA), and p.Val600Arg (c.1798_1799delinsAG). All DNA and Protein changes are given with respect to BRAF reference sequence NM_004333.4